SpringWorks Therapeutics Inc
SWTX46.990USD
0.000
Market hours （ET）Quotes delayed by 15 min
3.52BMarket Cap
LossP/E TTM
More Details of SpringWorks Therapeutics Inc Company
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
SpringWorks Therapeutics Inc Info
Ticker SymbolSWTX
Company nameSpringWorks Therapeutics Inc
IPO dateSep 13, 2019
CEOMr. Saqib Islam, J.D.
Number of employees368
Security typeOrdinary Share
Fiscal year-endSep 13
Address100 Washington Blvd
CitySTAMFORD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06902-9302
Phone12038839490
Websitehttps://www.springworkstx.com/
Ticker SymbolSWTX
IPO dateSep 13, 2019
CEOMr. Saqib Islam, J.D.
Company Executives of SpringWorks Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Chief Operating Officer
Chief Operating Officer
102.78K
--
Mr. Daniel S. (Dan) Lynch
Mr. Daniel S. (Dan) Lynch
Independent Chairman of the Board
Independent Chairman of the Board
82.94K
--
Dr. James (Jim) Cassidy, M.D., Ph.D.
Dr. James (Jim) Cassidy, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
35.86K
+5.56%
Mr. Bhavesh Ashar
Mr. Bhavesh Ashar
Chief Commercial Officer
Chief Commercial Officer
19.30K
--
Mr. Carlos Alban
Mr. Carlos Alban
Independent Director
Independent Director
15.38K
--
Mr. Francis (Frank) Perier, Jr.
Mr. Francis (Frank) Perier, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Herschel S. Weinstein, J.D.
Mr. Herschel S. Weinstein, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Independent Director
Independent Director
--
--
Mr. Daniel Pichl
Mr. Daniel Pichl
Chief People Officer
Chief People Officer
--
-100.00%
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Chief Operating Officer
Chief Operating Officer
102.78K
--
Mr. Daniel S. (Dan) Lynch
Mr. Daniel S. (Dan) Lynch
Independent Chairman of the Board
Independent Chairman of the Board
82.94K
--
Dr. James (Jim) Cassidy, M.D., Ph.D.
Dr. James (Jim) Cassidy, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
35.86K
+5.56%
Mr. Bhavesh Ashar
Mr. Bhavesh Ashar
Chief Commercial Officer
Chief Commercial Officer
19.30K
--
Mr. Carlos Alban
Mr. Carlos Alban
Independent Director
Independent Director
15.38K
--
Mr. Francis (Frank) Perier, Jr.
Mr. Francis (Frank) Perier, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2023Q4
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
49.09M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, May 20
Updated: Tue, May 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.38%
BlackRock Institutional Trust Company, N.A.
7.00%
State Street Global Advisors (US)
3.87%
T. Rowe Price Associates, Inc.
3.33%
Woodline Partners LP
2.85%
Other
73.56%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.38%
BlackRock Institutional Trust Company, N.A.
7.00%
State Street Global Advisors (US)
3.87%
T. Rowe Price Associates, Inc.
3.33%
Woodline Partners LP
2.85%
Other
73.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.71%
Sovereign Wealth Fund
2.43%
Individual Investor
1.22%
Investment Advisor/Hedge Fund
0.15%
Hedge Fund
0.05%
Other
93.43%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
68
414.43K
0.55%
-8.17M
2025Q1
573
77.70M
103.24%
-22.69M
2024Q4
490
88.41M
118.04%
-11.55M
2024Q3
479
87.46M
117.75%
-11.59M
2024Q2
454
81.87M
110.52%
-15.83M
2024Q1
437
83.09M
112.25%
-11.87M
2023Q4
403
80.24M
109.81%
+3.34M
2023Q3
387
75.55M
121.85%
-8.83M
2023Q2
384
76.79M
123.93%
-3.97M
2023Q1
390
73.34M
118.42%
-7.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
--
0%
+48.42K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
+110.88K
-100.00%
State Street Global Advisors (US)
--
0%
+77.66K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+74.00K
-100.00%
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
AltShares Event-Driven ETF
7.06%
AltShares Merger Arbitrage ETF
6.46%
First Trust Merger Arbitrage ETF
5.56%
iShares Genomics Immunology and Healthcare ETF
4.03%
ProShares Merger ETF
3.76%
First Trust Innovation Leaders ETF
1.45%
SPDR S&P Biotech ETF
1.41%
WisdomTree BioRevolution Fund
0.94%
Direxion Daily S&P Biotech Bull 3X Shares
0.76%
First Trust Small Cap Growth AlphaDEX Fund
0.5%
View more
AltShares Event-Driven ETF
Proportion7.06%
AltShares Merger Arbitrage ETF
Proportion6.46%
First Trust Merger Arbitrage ETF
Proportion5.56%
iShares Genomics Immunology and Healthcare ETF
Proportion4.03%
ProShares Merger ETF
Proportion3.76%
First Trust Innovation Leaders ETF
Proportion1.45%
SPDR S&P Biotech ETF
Proportion1.41%
WisdomTree BioRevolution Fund
Proportion0.94%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.76%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.5%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of SpringWorks Therapeutics Inc?
The top five shareholders of SpringWorks Therapeutics Inc are:
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 0.00 shares, accounting for 0.00% of the total shares.
State Street Global Advisors (US) holds 0.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 0.00 shares, accounting for 0.00% of the total shares.
State Street Global Advisors (US) holds 0.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of SpringWorks Therapeutics Inc?
The top three shareholder types of SpringWorks Therapeutics Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
How many institutions hold shares of SpringWorks Therapeutics Inc (SWTX)?
As of 2025Q2, 68 institutions hold shares of SpringWorks Therapeutics Inc, with a combined market value of approximately 414.43K, accounting for 0.55% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -102.69%.
What is the biggest source of revenue for SpringWorks Therapeutics Inc?
In FY2025Q1, the -- business generated the highest revenue for SpringWorks Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
